BDNF Val66Met genotype and 6-month remission rates in late-life depression

Pharmacogenomics Journal

Volumn 11, Issue 2, 2011, Pages 146-154

  Taylor, W D ^a   McQuoid, D R ^a   Ashley Koch, A ^a   MacFall, J R ^a   Bridgers, J ^a   Krishnan, R R ^a,b   Steffens, D C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

antidepressant response; BDNF; genetic polymorphism; geriatrics; major depressive disorder

Indexed keywords

AMFEBUTAMONE; BRAIN DERIVED NEUROTROPHIC FACTOR; METHIONINE; MIRTAZAPINE; NEFAZODONE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALINE; VENLAFAXINE;

AGED; ALLELE; ARTICLE; BRAIN DAMAGE; CAUCASIAN; CONTROLLED STUDY; ELECTROCONVULSIVE THERAPY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOTHERAPY; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL SUPPORT;

AGED; AMINO ACID SUBSTITUTION; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; METHIONINE; MIDDLE AGED; POINT MUTATION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; REMISSION INDUCTION; VALINE;

EID: 79953031271     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.12     Document Type: Article

References (42)

1. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001; 7: 541-547. (Pubitemid 32448319)
2. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116-1127.
3. Escobar ML, Figueroa-Guzman Y, Gomez-Palacio-Schjetnan A. In vivo insular cortex LTP induced by brain-derived neurotrophic factor. Brain Res 2003; 991: 274-279. (Pubitemid 37297961)
4. Nagappan G, Lu B. Activity-dependent modulation of the BDNF receptor TrkB: mechanisms and implications. Trends Neurosci 2005; 28: 464-471. (Pubitemid 41187795)
5. Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci 2001; 2: 24-32.
6. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64: 527-532.
7. Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003; 54: 703-709. (Pubitemid 37281386)
8. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-7547.
9. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev 2006; 58: 115-1134.
10. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-269. (Pubitemid 36144114)
11. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004; 24: 4401-4411. (Pubitemid 38608151)
12. Chen L, Lawlor DA, Lewis SJ, Yuan W, Abdollahi MR, Timpson NJ et al. Genetic association study of BDNF in depression: finding from two cohort studies and a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 814-821.
13. Verhagen M, van der Meij A, van Deurzen PA, Janzing JG, Arias-Vasquez A, Buitelaar JK et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry. E-pub ahead of print 15 October 2008.
14. Hwang JP, Tsai SJ, Hong CJ, Yang CH, Lirng JF, Yang YM. The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with geriatric depression. Neurobiol Aging 2006; 27: 1834-1837.
15. Taylor WD, Zuchner S, McQuoid DR, Steffens DC, Speer MC, Krishnan KR. Allelic differences in the BDNF val66met polymorphism in late-life depression. Am J Geriatr Psychiatry 2007; 15: 850-857.
16. Taylor WD, Zuchner S, McQuoid DR, Payne ME, MacFall JR, Steffens DC et al. The BDNF Val66Met polymorphism and cerebral white matter hyperintensities in late-life depression. Am J Geriatr Psychiatry 2008; 16: 263-271.
17. Taylor WD, Zuchner S, McQuoid DR, Steffens DC, Blazer DG, Krishnan KR. Social support in older individuals: the role of the BDNF Val66Met polymorphism. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1205-1212.
18. Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 2006; 1118: 176-182.
19. Yoshida K, Higuchi H, Kamata M, Takahasi H, Inoue K, Suzuki T et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharm 2007; 21: 650-656. (Pubitemid 47472727)
20. Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet 2003; 123: 19-22. (Pubitemid 37323258)
21. Kang RH, Chang HS, Wong ML, Choi MJ, Park JY, Lee HY et al. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharm. E-pub ahead of print 3 June 2009.
22. Robins LN, Helzer JE, Croughan J, Ratcliff KS. National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. Arch Gen Psychiatry 1981; 38: 381-389.
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389. (Pubitemid 9136500)
24. Steffens DC, Hays JC, Krishnan KRR. Disability in geriatric depression. Am J Geriatr Psychiatry 1999; 7: 34-40. (Pubitemid 29029827)
25. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992; 41: 237-248.
26. Landerman R, George LK, Campbell RT, Blazer DG. Alternative models of the stress buffering hypothesis. Am J Comm Psychol 1989; 17: 626-642.
27. George LK, Blazer DG, Hughes DC, Fowler N. Social support and the outcome of major depression. Br J Psychiatry 1989; 154: 478-485. (Pubitemid 19105227)
28. Folstein MF, Folstein SE, McHugh PR. Mini-mental state' a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
29. Steffens DC, McQuoid DR, Krishnan KRR. The Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED) approach. Psychopharmacol Bull 2002; 36: 58-68.
30. Taylor WD, MacFall JR, Payne ME, McQuoid DR, Steffens DC, Provenzale JM et al. Greater MRI lesion volumes in elderly depressed subjects than in control subjects. Psychiatry Res 2005; 139: 1-7. (Pubitemid 40800432)
31. Payne ME, Fetzer DL, MacFall JR, Provenzale JM, Byrum CE, Krishnan KRR. Development of a semi-automated method for quantification of MRI gray and white matter lesions in geriatric subjects. Psychiatry Res 2002; 115: 63-77. (Pubitemid 34880099)
32. Rimmler J, McDowell JG, Slotterback BD, Haynes CS, Menold MM, Rogala A et al. Development of a data coordinating center (DCC): Data quality control for complex disease studies. Am J Hum Genet (Suppl). 1998; 63: A240.
33. Zimmerman M, Posternak MA, Chelminski I. Defining remission on the Montgomery-Asberg Depression Rating Scale. J Clin Psychiatry 2004; 65: 163-168.
34. Holmbeck GN. Toward terminological, conceptual, and statistical clarity in the study of mediators and moderators: examples from the child-clinical and pediatric psychology literatures. J Consult Clin Psychol 1997; 65: 599-610. (Pubitemid 27343830)
35. Pezawas L, Meyer-Lindenberg A, Goldman AL, Verchinski BA, Chen G, Kolachana BS et al. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry 2008; 13: 709-716. (Pubitemid 351861533)
36. Trivedi MH, Rush AJ, Wisniewski S, Nierenberg AA, Warden D, Ritz L et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40. (Pubitemid 43050100)
37. Garza AA, Ha TG, Garcia C, Chen MJ, Russo-Neustadt AA. Exercise, antidepressant treatment, and BDNF mRNA expression in the aging brain. Pharmacol Biochem Behav 2004; 77: 209-220. (Pubitemid 38125152)
38. Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 2008; 43: 247-254.
39. Licinio J, Dong C, Wong ML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry 2009; 66: 488-497.
40. Cohen A, Houck PR, Szanto K, Dew MA, Gilman SE, Reynolds 3rd CF. Social inequalities in response to antidepressant treatment in older adults. Arch Gen Psychiatry 2006; 63: 50-56. (Pubitemid 43037468)
41. Alexopoulos GS, Kiosses DN, Heo M, Murphy CF, Shanmugham B, Gunning-Dixon F. Executive dysfunction and the course of geriatric depression. Biol Psychiatry 2005; 58: 204-210. (Pubitemid 41112268)
42. Erickson KI, Kim JS, Suever BL, Voss MW, Francis BM, Kramer AF. Genetic contributions to age-related decline in executive function: a 10-year longitudinal study of COMT and BDNF polymorphisms. Front Hum Neurosci 2008; 2: 11.